Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035683 | 0.88 | DYRK3 (0.48) | TGFBR1PRKD1DYRK3CLK1CLK2 | |
| SCHEMBL2229449 | 0.88 | TGFBR1 (0.56) | TGFBR1PRKD1LRRK2SYKRIPK2 | |
| SCHEMBL2197137 | 0.81 | TGFBR1 (0.50) | TGFBR1PRKD1LRRK2SYKMAPT | |
| SCHEMBL2200375 | 0.80 | MAPT (0.50) | TGFBR1PRKD1LRRK2SYKMAPT | |
| SCHEMBL2202465 | 0.79 | EGFR (0.61) | TGFBR1PRKD1KDR | |
| SCHEMBL2197036 | 0.78 | ABCG2 (0.54) | TGFBR1PRKD1DYRK3CLK1DYRK1A | |
| SCHEMBL2202747 | 0.77 | TGFBR1 (0.45) | TGFBR1PRKD1LRRK2SYKNPC1 | |
| SCHEMBL2202398 | 0.74 | IKBKB (0.47) | TGFBR1PRKD1DYRK3CLK1CLK2 | |
| SCHEMBL2201532 | 0.74 | KDR (0.47) | TGFBR1PRKD1LRRK2SYKMEN1 | |
| SCHEMBL4039259 | 0.74 | LRRK2 (0.47) | TGFBR1PRKD1LRRK2SYKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | claimed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | TGFBR1 1039/4885PRKD1 2525/4885DYRK3 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.